美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

GSK plc ADRhedged

67.19

+0.89981.36%

成交量：3

成交额：199

市值：67.19万

市盈率：- -

高：67.19

开：66.29

低：67.19

收：66.29

52周最高：85.03

52周最低：61.00

股本：1.00万

流通股本：1.00万

量比：0.01

换手率：0.03%

股息：2.08

股息率：3.09%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

葛兰素史克在伦敦上涨2.5%

每日经济新闻

葛兰素史克股价上涨2.5%，触及盘中高点，此前该公司公布的盈利报告超出预期。

葛兰素史克表示其目标是到2029年全面实现每年19亿英镑的成本节约。

葛兰素史克Q2调整后EPS为50.5便士超预期

盘前异动 | 存储、半导体板块集体下挫，西部数据、美光跌超5%，海力士跌超4%、英特尔、AMD跌超4%

老虎资讯综合

GSK凭借Jideytro获得美国食品药品监督管理局（FDA）的早期批准，正式进军肺癌药物市场

创新药研发加速遇“猴荒”

葛兰素史克(GSK)股票7月20日收盘下跌3.17%：释放什么信号？

TradingKey中文

葛兰素史克(GSK)股票7月17日盘中下跌3.06%：原因全解读

TradingKey中文

葛兰素史克(GSK)跌2.3% 止咳新药三期临床失利 20亿并购核心管线宣告终止开发

第3次更新-葛兰素史克因晚期临床试验未达预期，停止开发慢性咳嗽药物

英硅智能早盘涨超7% 与康哲药业达成AI+创新药研发新合作

前沿生物收入调减揭示渠道压力，经营亏损持续扩大

中国生物制药早盘涨超5% 与GSK进一步深化独家战略合作

GSK将两款呼吸疾病药物中国商业化权益授予正大天晴，MNC在华战略调整加速

中国生物制药分别与阿斯利康、葛兰素史克达成重要合作

葛兰素史克与中国生物制药深化战略合作

中国生物制药：深化与GSK呼吸领域战略合作

南方财经网

（活力中国调研行）上海生物医药产业规模破万亿张江药谷青年人才成创新药研发主力

中国新闻网

翰思艾泰-B(03378)：拟与华科前沿交叉研究中心打造新一代AI驱动的创新药研发范式

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/GSKH/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":67.1856,"timestamp":1791835200000,"preClose":66.2858,"halted":0,"volume":3,"delay":0,"changeRate":0.013574551412217988,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"盘前交易","change":0.8998,"latestTime":"10-13 08:22:38 EDT","open":66.2858,"high":67.1856,"low":67.1856,"amount":199,"amplitude":0,"askPrice":107.49,"askSize":200,"bidPrice":26.88,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791898200000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":67.1856,"nav":66.281474,"aum":662881.021474,"dividendRate":0.030899,"bidAskSpread":0,"volumeRatio":0.010482182491023583,"impliedVol":0.3657,"impliedVolPercentile":0.9925},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.010482182491023583,"shares":10001,"dividePrice":2.076,"high":67.1856,"amplitude":0,"preClose":66.2858,"low":67.1856,"week52Low":61,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":67.1856,"eps":0,"divideRate":0.030899,"volume":3,"delay":0,"ttmEps":0,"open":66.2858,"prevYearClose":68.2031,"prevWeekClose":66.2858,"prevMonthClose":68.5811,"prevQuarterClose":68.5811,"fiveDayClose":66.3846,"twentyDayClose":69.8025,"sixtyDayClose":71.9041},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654853009","title":"葛兰素史克在伦敦上涨2.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654853009","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654853009?lang=zh_cn&edition=fundamental","pubTime":"2026-07-28 19:12","pubTimestamp":1785237141,"startTime":"0","endTime":"0","summary":"葛兰素史克在伦敦上涨2.5%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823635566.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823635566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","GSK","BK4007","LU1829250122.USD","BK4588","GSKH","BK4532","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654800605","title":"葛兰素史克股价上涨2.5%，触及盘中高点，此前该公司公布的盈利报告超出预期。","url":"https://stock-news.laohu8.com/highlight/detail?id=2654800605","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654800605?lang=zh_cn&edition=fundamental","pubTime":"2026-07-28 19:09","pubTimestamp":1785236998,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK4585","BK4588","BK4532","GSK","GSKH","GSK.UK","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654900642","title":"葛兰素史克表示其目标是到2029年全面实现每年19亿英镑的成本节约。","url":"https://stock-news.laohu8.com/highlight/detail?id=2654900642","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654900642?lang=zh_cn&edition=fundamental","pubTime":"2026-07-28 19:04","pubTimestamp":1785236671,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","BK4585","LU1829250122.USD","BK4532","GSKH","BK4007","GSK","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654006157","title":"葛兰素史克Q2调整后EPS为50.5便士 超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2654006157","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654006157?lang=zh_cn&edition=fundamental","pubTime":"2026-07-28 19:03","pubTimestamp":1785236596,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1829250122.USD","GSK.UK","GSKH","BK4007","BK4585","BK4532","BK4588","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174181337","title":"盘前异动 | 存储、半导体板块集体下挫，西部数据、美光跌超5%，海力士跌超4%、英特尔、AMD跌超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174181337","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174181337?lang=zh_cn&edition=fundamental","pubTime":"2026-07-28 16:03","pubTimestamp":1785225827,"startTime":"0","endTime":"0","summary":"7月28日，美股盘前三大股指期货涨跌不一，道指期货升0.14%，标普500指数期货跌0.18%，纳指期货跌0.89%。存储概念股集体下挫，西部数据、闪迪、美光跌超5%，希捷科技跌超4%，SK海力士跌近4%；光通信概念股普跌，康宁跌超3%，CRDO跌超2%；半导体板块集体下跌，英特尔、AMD跌超4%，阿斯麦跌超3%；热门中概股盘前涨跌不一，网易涨近2%，金山云跌近2%，腾讯音乐跌超1%，小鹏集团跌近1%；","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDC","BOED","PYPL","SKHY","MULL","AMDU","GLWG","TME","PYPY","SNXX","SKDD","SKHX","SNDU","GSKH","SKHU","KO","SNDQ","BOEG","MUZ","ASMU","GLW","INTC","BA","AMDW","CRDO","DAMD","MUYY","AMYY","NTES","ASML","AMUU","XPEG","XPEV","LINT","SK","SKHZ","SNDK","ASMG","SNDG","AMDL","KC","AMDD","HYNX","PYPG","MUU","AMD","INTW","WDCX","CRDU","07709","AMDG","GSK","WDC","MIC","STX","MUD","MU","AMDY","BOEU","SKUU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653767521","title":"GSK凭借Jideytro获得美国食品药品监督管理局（FDA）的早期批准，正式进军肺癌药物市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2653767521","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653767521?lang=zh_cn&edition=fundamental","pubTime":"2026-07-23 02:12","pubTimestamp":1784743973,"startTime":"0","endTime":"0","summary":"更新 2-GSK凭借Jideytro获得美国食品药品监督管理局的早期批准，正式进军肺癌药物市场重写第1至4段，补充有关药品审批及近期交易的细节Padmanabhan Ananthan/Bhanvi Satija路透7月22日-葛兰素史克GSK.L周三表示，美国食品药品监督管理局已批准其用于治疗某种肺癌的药物。此次批准标志着GSK正式进军利润丰厚的肺癌治疗市场，且批准时间早于FDA设定的9月18日目标行动日期。预计美国食品药品监督管理局将于11月前就Nuvalent的第二款肺癌药物neladalkib作出审批决定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nL4T43O1YH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK.UK","BK4588","GSK","GSKH","LU1829250122.USD","BK4532","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653584157","title":"创新药研发加速遇“猴荒”","url":"https://stock-news.laohu8.com/highlight/detail?id=2653584157","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653584157?lang=zh_cn&edition=fundamental","pubTime":"2026-07-22 16:21","pubTimestamp":1784708497,"startTime":"0","endTime":"0","summary":"“要站在‘猴’里，不要像猴子一样站在那里。”资本市场从来不缺故事。近期，昭衍新药业绩暴增，原因是实验猴市场价格上涨，带动公司手里的“猴子资产”大幅增值，多家相关概念公司股价也跟风大涨。甚至有人顺藤摸瓜，挖出了“香蕉概念”。网友戏称：这是产业链挖掘最深的一次。一只猴子，为什么能扰动资本市场？答案藏在药物的研发链条里。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817277458.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817277458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","XLVI","WRND","BK4585","PBE","IBB","BIOY","BBP","SBIO","GDOC","APXH","GSKH","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653245757","title":"葛兰素史克(GSK)股票7月20日收盘下跌3.17%：释放什么信号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2653245757","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653245757?lang=zh_cn&edition=fundamental","pubTime":"2026-07-21 04:16","pubTimestamp":1784578570,"startTime":"0","endTime":"0","summary":"• 受到持续的Zantac诉讼债务以及监管不确定性的影响，GSK股价面临下行压力。\n• 疫苗市场竞争加剧和研发成本上升影响了投资者情绪。\n• 包括威廉指标（Williams %R）在内的技术指标显示该股可能面临潜在的抛售压力。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262042327-market-movers-gsk-20260720","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4007","GSKH","GSK.UK","LU1829250122.USD","GSK","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652287844","title":"葛兰素史克(GSK)股票7月17日盘中下跌3.06%：原因全解读","url":"https://stock-news.laohu8.com/highlight/detail?id=2652287844","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652287844?lang=zh_cn&edition=fundamental","pubTime":"2026-07-18 02:16","pubTimestamp":1784312169,"startTime":"0","endTime":"0","summary":"• 由于持续进行的善胃得（Zantac）诉讼及潜在的和解负债，葛兰素史克（GSK）股价面临波动。\n• 行业定价压力和机构投资转向导致股价表现走低。\n• 临床管线研究结果的不确定性以及汇率波动影响了该公司的估值和收益。","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262038450-market-movers-gsk-20260717","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSKH","BK4007","BK4588","BK4585","GSK.UK","BK4532","LU1829250122.USD","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652784289","title":"葛兰素史克(GSK)跌2.3% 止咳新药三期临床失利 20亿并购核心管线宣告终止开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652784289","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652784289?lang=zh_cn&edition=fundamental","pubTime":"2026-07-17 22:32","pubTimestamp":1784298747,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英国药企葛兰素史克 股价承压，报51.56美元，跌2.29%。该药物为高选择性 P2X3 受体拮抗剂，是 2023 年 GSK 斥 20 亿美元全额现金收购 Bellus Health 的核心资产，原本被市场寄予厚望，用于填补难治性慢性咳嗽临床空白。本次 20 亿并购的核心呼吸管线宣告失败，大幅削弱公司呼吸板块中长期增长预期，市场担忧并购投入回报不及预期；肠易激综合征赛道市场空间相对有限，难以完全对冲止咳适应症临床失利带来的估值压力。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGU1YzNhMmY0MDcxNDc2NDI4MDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302703","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CALF","GSK","KCE","XMMO","LU1829250122.USD","MYLD","BK4585","BK4532","BK4007","GSKH","GSK.UK","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652883682","title":"第3次更新-葛兰素史克因晚期临床试验未达预期，停止开发慢性咳嗽药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2652883682","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652883682?lang=zh_cn&edition=fundamental","pubTime":"2026-07-17 19:56","pubTimestamp":1784289375,"startTime":"0","endTime":"0","summary":"但也有人认为此次临床试验失败尚在可控范围内。两种剂量均未达到关键次要目标，包括来自“慢性咳嗽日记”的患者报告结果。该公司还计划分享相关数据，以促进对难治性慢性咳嗽这一目前治疗选择有限的疾病的科学理解。全球每年约有1000万患者罹患此病，该病症可能导致患者每天咳嗽超过900次。葛兰素史克于2023年以20亿美元收购Bellus Health公司，从而获得了该药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nL4T43J0WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GSK.UK","GSKH","BK4532","BK4585","BK4007","GSK","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162210","title":"英硅智能早盘涨超7% 与康哲药业达成AI+创新药研发新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162210","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651162210?lang=zh_cn&edition=fundamental","pubTime":"2026-07-13 10:02","pubTimestamp":1783908120,"startTime":"0","endTime":"0","summary":"　　英硅智能早盘涨超7%，截至发稿，股价上涨6.21%，报45.48港元，成交额3.32亿港元。　　7月13日，据英硅智能官微消息，公司宣布与康哲药业在中枢神经系统领域开展另一项AI驱动的药物发现合作。　　根据合作协议，双方将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，双方共同推进该研发项目的合作开发。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrnpk9058117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SG9999015978.USD","BK1191","IE00BMCWC346.EUR","BK4585","AIPO","IE00BGHQDM52.EUR","ARTY","BK4588","GSKH","SBIO","LU2488822045.USD","LFSC","BBP","WRND","SG9999015952.SGD","CHAT","QTOC","SG9999015986.USD","IE00BYV24P56.USD","VTHR","IBB","BK1593","SG9999004220.SGD","GDOC","IE00BVYPNP33.GBP","IE00BVYPNQ40.USD","00867","PBE","AGIX","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650902698","title":"前沿生物收入调减揭示渠道压力，经营亏损持续扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2650902698","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650902698?lang=zh_cn&edition=fundamental","pubTime":"2026-07-10 14:18","pubTimestamp":1783664280,"startTime":"0","endTime":"0","summary":"前沿生物近日就上交所2025年年报问询函作出回复，对收入确认调整、经销商库存、研发投入及现金流等问题逐一说明。回复内容揭示了公司在核心产品增长、渠道健康度和费用控制等方面面临的现实压力。艾可宁终端销售能否回暖、渠道库存能否有效消化、费用支出能否得到控制，仍是决定公司未来经营走向的关键变量。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-07-10/doc-inihhzry7114679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SPHQ","GSK.UK","LU1829250122.USD","GSK","BK4007","BK4532","GSKH","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650910625","title":"中国生物制药早盘涨超5% 与GSK进一步深化独家战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2650910625","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650910625?lang=zh_cn&edition=fundamental","pubTime":"2026-07-09 10:12","pubTimestamp":1783563120,"startTime":"0","endTime":"0","summary":"　　中国生物制药早盘涨超5%，截至发稿，股价上涨5.39%，现报5.08港元，成交额2.39亿港元。　　7月8日，中国生物制药发布公告，集团附属公司正大天晴药业集团股份有限公司进一步深化与葛兰素史克“GSK”于2026年5月达成的独家战略合作，推动两款呼吸领域重磅创新药物惠及更多中国患者。本次合作是集团与GSK战略合作的又一重要进展，标志着双方合作领域从肝病进一步拓展至呼吸系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-09/doc-inihench4479325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1829250122.USD","GSK.UK","BK4007","BK4532","01177","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK4585","BK1515","BK1589","HK0000165453.HKD","BK4588","BK1521","BK1191","GSKH","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649096193","title":"GSK将两款呼吸疾病药物中国商业化权益授予正大天晴，MNC在华战略调整加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2649096193","media":"蓝鲸财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649096193?lang=zh_cn&edition=fundamental","pubTime":"2026-07-08 16:50","pubTimestamp":1783500612,"startTime":"0","endTime":"0","summary":"而此前，就在今年5月，正大天晴获得GSK乙肝新药Bepirovirsen在中国内地的独家商业化权利。事实上，不只GSK，跨国药企在华战略近年来正在加速调整。一方面，MNC将成熟管线的商业化权益交给国内企业，另一方面，MNC正在加大力度购买中国药企的创新管线。从商业化到研发，内、外资药企的战略调整还在加速。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1783500577933587278","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["GSKH","BK4588","BK4585","GSK","GSK.UK","BK4007","BK4532","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649969580","title":"中国生物制药分别与阿斯利康、葛兰素史克达成重要合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649969580","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649969580?lang=zh_cn&edition=fundamental","pubTime":"2026-07-08 15:55","pubTimestamp":1783497300,"startTime":"0","endTime":"0","summary":"7月8日，中国生物制药有限公司（以下简称“中国生物制药”）公告称，将自主研发的慢性阻塞性肺疾病（COPD）创新药TQC3721（PDE3/4抑制剂）海外权益以总额最高19亿美元授权给阿斯利康，创下近三年中国呼吸领域单产品交易额之最；同日，中国生物制药还宣布将进一步深化与葛兰素史克（GSK）的战略合作，获得GSK两款全球重磅呼吸创新药在中国内地的独家商业化权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798367659.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798367659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSKH","IE00BZ08YS42.EUR","LU2237443382.USD","LU0432979614.USD","LU2237443895.HKD","LU0889565916.HKD","BK1589","LU0320765992.SGD","LU2468319806.SGD","LU0708994859.HKD","LU0058720904.USD","BK1515","AZN","BK4532","LU2237443622.USD","01177","LU0029864427.USD","LU0310800379.SGD","LU1267930573.SGD","LU2089984988.USD","BK4007","BK1191","LU2237443978.SGD","GSK.UK","GSK","BK4568","LU2237443465.HKD","LU2237443549.SGD","LU2462157665.USD","HK0000165453.HKD","AZNH","IE00B3T34201.USD","BK4588","LU2456880835.USD","IE00BZ08YT58.USD","BK4585","LU2236285917.USD","LU0289739699.SGD","BK1521","LU0109394709.USD","LU0128525929.USD","LU1829250122.USD","LU2417539215.USD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649027952","title":"葛兰素史克与中国生物制药深化战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649027952","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649027952?lang=zh_cn&edition=fundamental","pubTime":"2026-07-08 12:14","pubTimestamp":1783484047,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK1191","GSK","HK0000165453.HKD","BK4585","BK4588","BK1521","BK1515","IE00BZ08YT58.USD","BK4532","BK4007","LU1829250122.USD","GSK.UK","01177","GSKH","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649072952","title":"中国生物制药：深化与GSK呼吸领域战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649072952","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649072952?lang=zh_cn&edition=fundamental","pubTime":"2026-07-08 12:06","pubTimestamp":1783483560,"startTime":"0","endTime":"0","summary":"【中国生物制药：深化与GSK呼吸领域战略合作】南财智讯7月8日电，中国生物制药（01177.HK）发布自愿公告，宣布其附属公司正大天晴药业集团股份有限公司进一步深化与葛兰素史克（GSK）于2026年5月达成的独家战略合作，获得GSK两款呼吸领域创新药——氟替美维吸入粉雾剂（商品名：全再乐）和乌美溴铵维兰特罗吸入粉雾剂（商品名：欧乐欣）在中国内地的商业化权益，包括进口、分销、医院准入及推广活动，相关销售收入全额确认为正大天晴营业收入。本次合作系双方继肝病领域后首次拓展至呼吸系统疾病，标志本集团呼吸管线从研发向商业化全面升级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798154841.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798154841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","IE00BZ08YT58.USD","BK1191","BK4532","BK4588","IE00BZ08YR35.GBP","LU1829250122.USD","GSK.UK","01177","BK1521","GSKH","IE00BZ08YS42.EUR","HK0000165453.HKD","BK4007","GSK","BK1589","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649952006","title":"（活力中国调研行）上海生物医药产业规模破万亿 张江药谷青年人才成创新药研发主力","url":"https://stock-news.laohu8.com/highlight/detail?id=2649952006","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649952006?lang=zh_cn&edition=fundamental","pubTime":"2026-07-08 11:56","pubTimestamp":1783482969,"startTime":"0","endTime":"0","summary":"中新网上海7月8日电(杨海燕马佳佳)“我们对青年人才‘如饥似渴’，上海团队有180多名全职员工，90%以上都是40岁以下的青年人才。”英硅智能全球对外合作负责人、副总裁王珏7日在“活力中国调研行”主题采访活动中介绍道。在上海张江药谷，这片曾经的农田已崛起为世界级生物医药创新高地，而活跃其中的青年人才，正成为推动创新药研发的主力军。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798154946.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798154946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XBI","BK4588","161726","399441","GSKH","IBB","LFSC","SBIO","BK4581","WRND","BBP","PBE","BK4585","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984355","title":"翰思艾泰-B(03378)：拟与华科前沿交叉研究中心打造新一代AI驱动的创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984355","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984355?lang=zh_cn&edition=fundamental","pubTime":"2026-07-07 18:57","pubTimestamp":1783421872,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B 发布公告，为充分发挥产学研结合的优势，加速生物医药研发创新，公司于近日与华科—澳城大高等研究院前沿交叉研究中心正式签署了《“人工智能药物研发联合实验室”合作共建协议》。双方将依托华科前沿交叉研究中心的AI平台，以及翰思艾泰在创新药研发的丰富经验和对疾病领域的深度认知，围绕抗体发现与分子设计展开深度合作，共同打造新一代AI驱动的创新药研发范式。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1173","PBE","AGIX","LFSC","BK1161","AIPO","ARTY","WRND","IBB","SBIO","BK4588","CHAT","03378","BK1535","GDOC","VTHR","BK4585","QTOC","BBP","GSKH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":91,"code":"91000000","status":"200"}]}}